SUNNYVALE, Calif., Nov. 8, 2017 /PRNewswire/ -- November 11, 2017 marks Veterans Day in the
United States, a day to publicly recognize and honor those
people who have served, or are serving, in the Armed Services.
Accuray Incorporated (NASDAQ: ARAY) employees who have aided their
country through military duty are now providing another type of
service to military personnel. Each day, it is their mission to
ensure that the radiation therapy systems the company manufactures
are in prime working condition and ready when needed to provide the
best possible treatment to people diagnosed with cancer.
"At Accuray, more than 50 percent of the U.S. Field Service Team
has served our country through military duty. We believed it was
important to act selflessly, to do everything we could to help
others, and have carried these values over to the work that we're
currently doing," said Kevin
Brigham, Senior Field Service Engineer at Accuray; former
radar technician in the U.S. Navy. "We're committed to ensuring
that our radiation therapy systems are operating the way they
should, so clinicians are able to do their jobs – to provide
effective treatments to patients who may benefit from radiation
therapy."
According to a 2012 U.S. Veterans Affairs (VA) study of VA
cancer patients, 97.5% of whom were male, the five most frequently
diagnosed cancers were prostate, lung and bronchial, colorectal,
urinary and bladder cancers, and skin melanomas. While this mirrors
the most commonly diagnosed cancers in the general population of
American men, veterans are at higher risk for developing these
cancers, which are often effectively treated using targeted
radiation therapy.
Through the VA Choice Program, established as part of the
Veterans Access, Choice, and Accountability Act of 2014 (VACAA),
veterans enrolled in VA health can receive care within their
community or see a cancer specialist with the most advanced
technology, such as the Accuray CyberKnife®, Radixact™ and
TomoTherapy® Systems, instead of waiting for a VA appointment or
travelling to a VA facility. The innovative Accuray Systems were
designed to provide precise radiation treatments which minimize
exposure to healthy tissue and measurably reduce associated side
effects.
"As a veteran, I'm proud that Accuray supports the military
community through employment opportunities and educational efforts
around the VA Choice Program. While very different, each are
critical to the well-being of the esteemed military personnel who
have served our country," said Andy
Kirkpatrick, Senior Vice President, Global Operations and
R&D at Accuray; former nuclear engineer and submarine officer
in the U.S. Navy.
"I joined TomoTherapy, Incorporated, now Accuray, almost 14
years ago. As one of the first 100 employees, I've seen the
evolution of the TomoTherapy platform. I was impressed with the
system when it was first introduced and am now blown away by the
enhancements which have been made to ensure patients receive the
optimal treatment for their condition. I'm gratified that we are
working to improve veterans' access to this technology, and our
CyberKnife platform, through the VA Choice Program," commented
Robert Sinklair, Engineering
Technician IV at Accuray; former aerographers mate in the U.S.
Navy.
Important Safety Information
For Important Safety Information please refer
to http://www.accuray.com/safety-statement
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical results, our
ability to provide veterans with access to our technology, and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available
to Accuray at the time those statements are made and/or
management's good faith belief as of that time with respect to
future events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Sherry Feldberg
MSLGROUP
+1 (781) 684-0770
accuray@mslgroup.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/accuray-military-veterans-support-us-veteran-community-300551578.html
SOURCE Accuray Incorporated